Get the Stockscreener App
2.67
2.91%
-0.08
Redhill Biopharma Ltd Adr stock is traded at $2.67, with a volume of 7,929.
It is down -2.91% in the last 24 hours and down -19.82% over the past month.
See More
Previous Close:
$2.75
Open:
$2.71
24h Volume:
7,929
Relative Volume:
0.10
Market Cap:
$3.81M
Revenue:
$35.75M
Net Income/Loss:
$11.57M
P/E Ratio:
-0.7014
EPS:
-3.8069
Net Cash Flow:
$-26.25M
1W Performance:
-10.70%
1M Performance:
-19.82%
6M Performance:
-69.06%
1Y Performance:
-79.85%
1-Day Range:
$2.6602
$2.80
1-Week Range:
$2.64
$3.10
52-Week Range:
$2.47
$20.28
Redhill Biopharma Ltd Adr Stock (RDHL) Company Profile
Compare RDHL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RDHL
Redhill Biopharma Ltd Adr
|
2.67 | 3.81M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
ZTS
Zoetis Inc
|
164.01 | 73.07B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.05 | 47.43B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.27 | 45.72B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.08 | 17.60B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.83 | 14.03B | 612.78M | -86.37M | -62.91M | -0.87 |
Redhill Biopharma Ltd Adr Stock (RDHL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-31-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-11-20 | Initiated | BTIG Research | Buy |
| Jul-12-19 | Upgrade | WBB Securities | Buy → Strong Buy |
| Mar-12-19 | Upgrade | WBB Securities | Speculative Buy → Buy |
| Jan-26-18 | Initiated | Nomura | Buy |
| Oct-06-17 | Initiated | Seaport Global Securities | Buy |
| Oct-04-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-17 | Reiterated | FBR & Co. | Outperform |
| Jul-27-16 | Reiterated | FBR Capital | Outperform |
| Sep-29-15 | Initiated | Nomura | Buy |
| Jul-29-15 | Reiterated | ROTH Capital | Buy |
| Jun-17-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-15 | Reiterated | ROTH Capital | Buy |
View All
Redhill Biopharma Ltd Adr Stock (RDHL) Latest News
RedHill Biopharma targets UK approval for H. pylori therapy - Investing.com India
RedHill Biopharma targets UK approval for H. pylori therapy By Investing.com - Investing.com South Africa
Redhill Biopharma stock hits 52-week low at $3 amid steep annual decline By Investing.com - Investing.com South Africa
Redhill Biopharma stock hits 52-week low at $3 amid steep annual decline - Investing.com
What Did We Note About Insider Trading At Redhill Biopharma Ltd. ADR (NASDAQ: RDHL)? - Stocks Register
Hyloris secures global rights to RedHill’s RHB-102 - Investing.com India
Redhill Biopharma stock hits 52-week low at $4.79 - Investing.com India
Earnings call transcript: RedHill Biopharma Q1 2022 sees revenue dip - Investing.com
RedHill tests opaganib with Bayer's drug in prostate cancer study By Investing.com - Investing.com South Africa
RedHill tests opaganib with Bayer's drug in prostate cancer study - Investing.com India
RedHill stock rises on expanded Medicare coverage - Investing.com
RedHill stock rises on expanded Medicare coverage By Investing.com - Investing.com South Africa
GAMMA Investing LLC Buys 595 Shares of ArcelorMittal S.A. (NYSE:MT) - Defense World
RedHill wins $8 million judgment in New York court - Investing.com India
RedHill Biopharma: FDA Accepts TALICIA’s NDA - Investing.com
COVID-19 Competitive Landscape 2024 (Updated) - openPR
BARDA funds RedHill's opaganib for Ebola treatment - Investing.com
Medi-Cal extends Talicia access for 15 million Californians - Investing.com
RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines - Yahoo Finance
Talicia® Launched in the United Arab Emirates - Yahoo Finance
Redhill Biopharma stock hits 52-week high of $8.03 amid volatility - Investing.com
RedHill Biopharma Announces Positive Obesity and Diabetes Results with Opaganib - Investing.com
RedHill Biopharma Announces Plan to Implement ADS Ratio Change - PR Newswire
symbol__ Stock Quote Price and Forecast - CNN
Balancing Acidity: Exploring the Proton Pump Inhibitors Market - openPR
RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034 - PR Newswire
Phil and RedHill Biopharma Partner to Increase Access to Talicia® - Business Wire
Peptic Ulcer Drugs Market Drivers Analysis | CAGR of 3.5% - Market.us
Benign Growth For RedHill Biopharma Ltd. (NASDAQ:RDHL) Underpins Stock's 41% Plummet - Yahoo Finance
RedHill presents New Talicia® and Movantik® data analyses at ACG 2022 - EurekAlert
Cathie Wood Predictions 2022 - New Trader U
RedHill presents new Talicia® data analyses at DDW 2022 - EurekAlert
RedHill Biopharma Stock: Looking At An Unexciting Dead-End (NASDAQ:RDHL) - Seeking Alpha
RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D - PR Newswire
RedHill Gets Nod in Brazil for Coronavirus Study on Opaganib - Yahoo Finance
AstraZeneca divestment of Movantik to RedHill Biopharma completed - AstraZeneca
The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement - Yahoo Finance
RedHill Biopharma to Focus Commercial Efforts on Talicia® - GlobeNewswire
Is Senseonics Holdings, Inc. (SENS) Going to Burn These Hedge Funds? - Yahoo Finance
RedHill Biopharma's Drug Pipeline May Merit Substantial Upside, And Potential Catalysts Are On The Horizon - Seeking Alpha
RedHill Biopharma files for further Nasdaq offering - גלובס
RedHill Biopharma (RDHL) Stock Price, News & Analysis - MarketBeat
Redhill Biopharma Ltd Adr Stock (RDHL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.73%
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):